NCT00634569已完成4 期
Evaluation of the Efficacy and Safety of Flebogamma 5% DIF [Immune Globulin Intravenous (Human)] for Replacement Therapy in Pediatric Subjects With Primary Immunodeficiency Diseases.
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 13
- 主要终点
- Serious Bacterial Infections.
研究概览
简要总结
This is a multi-center, open-label study to assess the efficacy and safety of Flebogamma 5% DIF in the pediatric population.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 16 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The subject is between 2 and 16 years old, of either sex, belonging to any ethnic group, and above a minimum weight of 10 kg (this weight is based on the amount of blood required for testing).
- •The subject has a primary immunodeficiency disease, (e.g., common variable immunodeficiency, X-linked and autosomal forms of agammaglobulinemia, hyper-IgM syndrome, Wiskott-Aldrich Syndrome).
- •The subject has been receiving licensed IGIV replacement therapy at a dose that has not changed by + 50% of the mean dose on a mg/kg basis for at least 3 months before study entry and has maintained a trough level at least 300 mg/dL above baseline serum IgG levels.
- •Trough levels of IgG, dose of IGIV, and treatment intervals for the last 2 consecutive routine IGIV treatments must be documented for each subject before the first infusion in this study can be administered.
- •If a subject is an adolescent female (> 12 years of age) who is or becomes sexually active, she must have a negative result on a pregnancy test (HCG-based assay).
- •The subject, if old enough (generally 6 years to 16) has signed an informed Child Assent form and the subject's parent or legal guardian has signed an informed consent form, both approved by the Institutional Review Board.
排除标准
- •Adult patient (> 17 years old).
- •The subject has a history of any severe anaphylactic reaction to blood or any blood-derived product.
- •The subject is known to be intolerant to any component of the products, such as sorbitol (i.e., intolerance to fructose).
- •The subject has selective IgA deficiency or has demonstrable antibodies to IgA.
- •The subject is currently receiving, or has received, any investigational agent within the prior 3 months.
- •The subject has been exposed to blood or any blood product or derivative within the last 6 months, other than a commercially available IGIV.
- •The adolescent subject is pregnant or is nursing.
- •The subject, at screening, has levels greater than 2.5 times the upper limit of normal as defined at the central laboratory for pediatric patients of any of the following:
- •The subject has a severe pre-existing renal impairment (defined by serum creatinine greater than 2 times the ULN or BUN greater than 2.5 times the ULN for that laboratory, or any subject who is on dialysis) or any history of acute renal failure.
- •The subject has a history of DVT or thrombotic complications of IGIV therapy.
- •The subject suffers from any acute or chronic medical condition (e.g., renal disease or predisposing conditions for renal disease, coronary artery disease, or protein losing state) that, in the opinion of the Investigator, may interfere with the conduct of the study.
- •The subject has an acquired medical condition such as lymphocytic leukemia, chronic or recurrent neutropenia (ANC less than 1000), or AIDS known to cause secondary immune deficiency, or is s/p hematopoetic stem cell transplantation.
- •The subject is receiving the following medication:
- •Systemic corticosteroids (long-term, i.e., not intermittent or burst, daily, > 1 mg of prednisone equivalent/kg/day). Topical steroids (ie- nasal, inhaled for asthma, and/or skin preparations for eczema) are not exclusionary.
- •Immunosuppressive drugs
- •Immunomodulatory drugs
- •The subject has non-controlled arterial hypertension (systolic blood pressure > 160 mm Hg and/or diastolic blood pressure > 100 mm Hg).
- •The subject has anemia (hemoglobin < 10 g/dL) at screening.
- •The subject and/or parent/legal guardian of the subject is unlikely to adhere to the protocol requirements of the study or is likely to be uncooperative or unable to provide from the patient a storage serum sample at the screening visit. (Please note, a pre-treatment serum sample to be stored at -94° F (-70º C) for possible future testing is absolutely required).
结局指标
主要结局
Serious Bacterial Infections.
时间窗: 12 months
Total number of Bacterial pneumonia, bacteremia or sepsis, osteomyelitis/septic arthritis, visceral abscess or bacterial meningitis
次要结局
- Days of School/Usual Activities Missed Per Year(12 months)
- Number of Days on Antibiotics (Prophylactic and Therapeutic).(12 months)
- Number of Visits to Physician/ER Room for Acute Problems(12 months)
- Other Infections Documented by Fever and Physical Exam or Positive Radiograph.(12 months)
- Number of Infectious Episodes Per Year(12 months)
- Number of Adverse Events(12 months)
- Days of Hospitalization Per Year(12 months)
研究者
研究点 (13)
Loading locations...
相似试验
尚未招募
2 期
A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk FactorsNon Small Cell Lung CancerNCT06143735Tianjin Medical University Cancer Institute and Hospital99
已完成
1 期
A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaLymphomaNCT04657302Hoffmann-La Roche30
终止
不适用
Safety and Efficacy of Fibryga in Congenital Fibrinogen DeficiencyCongenital Fibrinogen DeficiencyNCT03793426Octapharma7
已完成
3 期
An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate TherapyArthritis, RheumatoidNCT00973479Centocor, Inc.592
已完成
3 期
PSUNRISE - Prospective Study Using Remicade in Psoriasis Patients With an Inadequate Response to EtanerceptPsoriasisNCT00527072Centocor Ortho Biotech Services, L.L.C.217